Bruton’s tyrosine kinase (BTK) inhibitors, such as ibrutinib, zanubrutinib, and acalabrutinib, are used to treat non-Hodgkin lymphoma, among other hematologic malignancies and inflammatory diseases. Here, BTK is linked to non-Hodgkin lymphoma.